Of Screening, Stratification, and Scores

Technological innovations including risk-stratification algorithms and large databases of longitudinal population health data and genetic data are allowing us to develop a deeper understanding how individual behaviors, characteristics, and genetics are related to health risk. The clinical implementation of risk-stratified screening programmes that utilise risk scores to allocate patients into tiers of health risk is foreseeable in the future. Legal and ethical challenges associated with risk-stratified cancer care must, however, be addressed. Obtaining access to the rich health data that are required to perform risk-stratification, ensuring equitable access to risk-stratified care, ensuring that algorithms that perform risk-scoring are representative of human genetic diversity, and determining the appropriate follow-up to be provided to stratification participants to alert them to changes in their risk score are among the principal ethical and legal challenges. Accounting for the great burden that regulatory requirements could impose on access to risk-scoring technologies is another critical consideration.

[1]  B. Knoppers,et al.  Biomedical Data Identifiability in Canada and the European Union: From Risk Qualification to Risk Quantification? , 2021, SCRIPT-ed.

[2]  Jennifer D. Brooks,et al.  Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I) , 2021, Journal of personalized medicine.

[3]  B. Køster Reduced cancer risk from healthier lifestyle , 2021, Acta oncologica.

[4]  R. Houlston,et al.  Will polygenic risk scores for cancer ever be clinically useful? , 2021, npj Precision Oncology.

[5]  P. Donnelly,et al.  Validation of an Integrated Risk Tool, Including Polygenic Risk Score, for Atherosclerotic Cardiovascular Disease in Multiple Ethnicities and Ancestries. , 2021, The American journal of cardiology.

[6]  Xiaoping Zhou,et al.  On cross-ancestry cancer polygenic risk scores , 2021, medRxiv.

[7]  Jennifer D. Brooks,et al.  Women’s Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada , 2021, Journal of personalized medicine.

[8]  Paul J. Harrison,et al.  Ethical Issues in Consent for the Reuse of Data in Health Data Platforms , 2021, Science and Engineering Ethics.

[9]  Alicia R. Martin,et al.  Leveraging fine-mapping and non-European training data to improve trans-ethnic polygenic risk scores , 2021, medRxiv.

[10]  D. Easton,et al.  CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[11]  A. Price,et al.  Improving the trans-ancestry portability of polygenic risk scores by prioritizing variants in predicted cell-type-specific regulatory elements , 2020, Nature Genetics.

[12]  J. Kaye,et al.  Governance of research consortia: challenges of implementing Responsible Research and Innovation within Europe , 2020, Life Sciences, Society and Policy.

[13]  Mark Barnes,et al.  How to fix the GDPR's frustration of global biomedical research , 2020, Science.

[14]  Jessica L Roberts,et al.  GENETIC DUTIES. , 2020, William and Mary law review.

[15]  Jeroen J. van den Broek,et al.  Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History , 2020, Journal of the National Cancer Institute.

[16]  Jingmei Li,et al.  European polygenic risk score for prediction of breast cancer shows similar performance in Asian women , 2020, Nature Communications.

[17]  L. Esserman,et al.  Personalized early detection and prevention of breast cancer: ENVISION consensus statement , 2020, Nature Reviews Clinical Oncology.

[18]  O. Topolcan,et al.  Biobanks in the era of big data: objectives, challenges, perspectives, and innovations for predictive, preventive, and personalised medicine , 2020, EPMA Journal.

[19]  E. Vassos,et al.  Polygenic risk scores: from research tools to clinical instruments , 2020, Genome Medicine.

[20]  R. Manchanda,et al.  Population-based Genetic Testing for Precision Prevention , 2020, Cancer Prevention Research.

[21]  P. Pharoah,et al.  The challenge of early detection in cancer , 2020, Science.

[22]  L. Susswein,et al.  Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment. , 2020, Journal of genetic counseling.

[23]  B. Meiser,et al.  Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field , 2020, Breast Cancer Research.

[24]  H. Torun,et al.  A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification , 2019, Hormones and Cancer.

[25]  P. van Baal,et al.  Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained. , 2019, American journal of preventive medicine.

[26]  R. Eeles,et al.  Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study , 2019, PLoS medicine.

[27]  S. Duffy,et al.  Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines , 2019, Annals of Internal Medicine.

[28]  B. Knoppers,et al.  A Legal Duty of Genetic Recontact in Canada , 2019 .

[29]  M. Khoury,et al.  Perspective: The Clinical Use of Polygenic Risk Scores: Race, Ethnicity, and Health Disparities. , 2019, Ethnicity & disease.

[30]  Rachel L. Ross,et al.  Implementing Risk Stratification in Primary Care: Challenges and Strategies , 2019, The Journal of the American Board of Family Medicine.

[31]  W. V. van Harten,et al.  A duty to recontact in genetics: context matters , 2019, Nature reviews genetics.

[32]  X. Castells,et al.  A systematic review and quality assessment of individualised breast cancer risk prediction models , 2019, British Journal of Cancer.

[33]  R. Tuttle,et al.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. , 2019, The Journal of clinical endocrinology and metabolism.

[34]  E. Ziv,et al.  A response to “Personalised medicine and population health: breast and ovarian cancer” , 2019, Human Genetics.

[35]  L. Hindorff,et al.  Defining and Achieving Health Equity in Genomic Medicine. , 2019, Ethnicity & disease.

[36]  C. Alfano,et al.  Personalized Risk-Stratified Cancer Follow-Up Care: Its Potential for Healthier Survivors, Happier Clinicians, and Lower Costs. , 2019, Journal of the National Cancer Institute.

[37]  M. García-Closas,et al.  BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.

[38]  W. Harten,et al.  A Duty to Recontact in the Context of Genetics: Futuristic or Realistic? , 2018, European Journal of Health Law.

[39]  Paul Quinn,et al.  Big genetic data and its big data protection challenges , 2018, Comput. Law Secur. Rev..

[40]  S. Manley,et al.  Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.

[41]  Timothy Shin Heng Mak,et al.  Tutorial: a guide to performing polygenic risk score analyses , 2018, bioRxiv.

[42]  W. Willett,et al.  Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case–control study , 2018, PLoS medicine.

[43]  E. Spackman,et al.  Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis , 2018, Public Health Reviews.

[44]  P. Pharoah,et al.  Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer , 2018, JAMA oncology.

[45]  Vence L Bonham,et al.  The Clinical Imperative for Inclusivity: Race, Ethnicity, and Ancestry (REA) in Genomics , 2018, bioRxiv.

[46]  D. Curtis Polygenic risk score for schizophrenia is more strongly associated with ancestry than with schizophrenia , 2018, bioRxiv.

[47]  P. Marshall,et al.  Including all voices in international data-sharing governance , 2018, Human Genomics.

[48]  I. Cohen Is There a Duty to Share Healthcare Data , 2018 .

[49]  Andrew E. Teschendorff,et al.  Epigenome-based cancer risk prediction: rationale, opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[50]  T. Dent,et al.  Risk stratification, genomic data and the law , 2018, Journal of Community Genetics.

[51]  Urs Gasser,et al.  Big Data, Health Law, and Bioethics , 2018 .

[52]  S. Hill Introducing genomics into cancer care , 2018, The British journal of surgery.

[53]  Rachel L. Ross,et al.  Perceptions of Risk Stratification Workflows in Primary Care , 2017, Healthcare.

[54]  Ewan Birney,et al.  Genomics in healthcare: GA4GH looks to 2022 , 2017, bioRxiv.

[55]  Stephen Armstrong Data, data everywhere: the challenges of personalised medicine , 2017, British Medical Journal.

[56]  S. Schicktanz,et al.  Why take part in personalised cancer research? Patients’ genetic misconception, genetic responsibility and incomprehension of stratification—an empirical‐ethical examination , 2017, European journal of cancer care.

[57]  E. Álava,et al.  Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH , 2017, Clinical and Translational Oncology.

[58]  Tal Z. Zarsky,et al.  Incompatible: The GDPR in the Age of Big Data , 2017 .

[59]  A. Clarke,et al.  Recontacting in clinical practice: the views and expectations of patients in the United Kingdom , 2017, European Journal of Human Genetics.

[60]  B. Karlan,et al.  Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? , 2017, Gynecologic oncology.

[61]  Victor Osamor,et al.  Development of Bioinformatics Infrastructure for Genomics Research. , 2017, Global heart.

[62]  M. Sekerija,et al.  Cancer screening: policy recommendations on governance, organization and evaluation of cancer screening , 2017 .

[63]  G. Lippi,et al.  BRCA population screening for predicting breast cancer: for or against? , 2017, Annals of translational medicine.

[64]  J. Struijs,et al.  Defining Population Health Management: A Scoping Review of the Literature. , 2017, Population health management.

[65]  R. Wolff,et al.  The Interaction between Genetic Ancestry and Breast Cancer Risk Factors among Hispanic Women: The Breast Cancer Health Disparities Study , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[66]  G. V. Van Norman Drugs and Devices , 2016, JACC. Basic to translational science.

[67]  L. Klotz,et al.  Active Surveillance for Intermediate Risk Prostate Cancer , 2016, Prostate Cancer and Prostatic Diseases.

[68]  Annelien L Bredenoord,et al.  Big Data in medical research and EU data protection law: challenges to the consent or anonymise approach , 2015, European Journal of Human Genetics.

[69]  S. Grosse Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis , 2015, Healthcare.

[70]  M. Blute,et al.  Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. , 2015, Urologic oncology.

[71]  S. Duffy,et al.  Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC , 2015, British Journal of Cancer.

[72]  Jane E. Carpenter,et al.  Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.

[73]  A. Price,et al.  Explicit modeling of ancestry improves polygenic risk scores and BLUP prediction , 2014, bioRxiv.

[74]  S. Duffy,et al.  Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis , 2014, Genetics in Medicine.

[75]  B. Knoppers,et al.  The ethical framing of personalized medicine , 2014, Current opinion in allergy and clinical immunology.

[76]  M. Piccart,et al.  Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  Aaron S Kesselheim,et al.  FDA regulation of mobile health technologies. , 2014, The New England journal of medicine.

[78]  D. Easton,et al.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.

[79]  F. Carinci,et al.  Health research and systems’ governance are at risk: should the right to data protection override health? , 2013, Journal of Medical Ethics.

[80]  C. Catton,et al.  The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[81]  D G Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2013, British Journal of Cancer.

[82]  D. Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2012, The Lancet.

[83]  Stephen T Holgate,et al.  The future of technologies for personalised medicine. , 2012, New biotechnology.

[84]  M. Verma Personalized Medicine and Cancer , 2012, Journal of personalized medicine.

[85]  Kensaku Kawamoto,et al.  Bmc Medical Informatics and Decision Making a National Clinical Decision Support Infrastructure to Enable the Widespread and Consistent Practice of Genomic and Personalized Medicine , 2009 .

[86]  A. Andermann,et al.  Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. , 2008, Bulletin of the World Health Organization.

[87]  J. Gray,et al.  Maximising benefit and minimising harm of screening , 2008, BMJ : British Medical Journal.

[88]  Larry J. Brindza,et al.  What is a premarket notification 510(k) , 1980 .

[89]  M. Zavon Principles and Practice of Screening for Disease. , 1969 .

[90]  Patricia A. H. Williams,et al.  Software as a Medical Device (SaMD): Useful or Useless Term? , 2021, HICSS.

[91]  Alicia R. Martin,et al.  Leveraging fine-mapping and non-European training data to improve cross-population polygenic risk scores , 2021 .

[92]  John W. Loonsk,et al.  A proposed national research and development agenda for population health informatics: summary recommendations from a national expert workshop , 2017, J. Am. Medical Informatics Assoc..

[93]  S. Narod,et al.  The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy , 2017, Breast Cancer Research and Treatment.

[94]  M. Roobol,et al.  Risk stratification in prostate cancer screening , 2013, Nature Reviews Urology.

[95]  L. Klotz Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention , 2008, Nature Clinical Practice Urology.

[96]  L. Katz,et al.  Medical devices. , 1985, Dimensions in health service.

[97]  Data saves lives: reshaping health and social care with data , 2022 .